FDA Approved Indications for this Orphan Drug:

Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

FDA Marketing Approval issued as of:
06/11/1996

Orphan Drug exclusivity ends on:
06/11/2003
Company Making and Marketing this drug:
Amedra Pharmaceuticals LLC

FDA Designation Date:
1/17/96

FDA Drug Designation:
Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).